Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC
“The CALGB/SWOG 80405 trial was designed and formulated in 2005, and the rationale was simple: we had new drugs –bevacizumab and cetuximab– and the study was designed to determine if one was better than the other in first-line for patients with colon cancer,” said lead study author Alan P. Venook, distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco, USA. The CALGB/SWOG 80405 trial studied patients whose tumours were KRAS wild-type at codons 12 and 13. …